Altimmune (ALT) Change in Acquisitions & Divestments (2017 - 2026)

Altimmune (ALT) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $39.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 4.16% year-over-year to $39.6 million; the TTM figure through Mar 2026 stood at $154.6 million (up 38.77% YoY), while the FY2025 annual figure was $153.0 million, up 75.15% from the prior year.
• Change in Acquisitions & Divestments climbed to $39.6 million in Q1 2026 per ALT's latest filing, from $9.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $105.5 million in Q2 2025 and bottomed at $9.4 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $31.9 million across 4 years, with a median of $26.4 million in 2023.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 441.28% in 2025 and fell as far as 65.0% in 2025.
• Altimmune's Change in Acquisitions & Divestments stood at $25.9 million in 2023, then advanced by 3.78% to $26.8 million in 2024, then sank by 65.0% to $9.4 million in 2025, then soared by 321.65% to $39.6 million in 2026.
• Business Quant data shows ALT's Change in Acquisitions & Divestments at $39.6 million in Q1 2026, $9.4 million in Q4 2025, and $105.5 million in Q2 2025.